Cargando…
Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233242/ https://www.ncbi.nlm.nih.gov/pubmed/35499624 http://dx.doi.org/10.2337/db22-0097 |
_version_ | 1784735717937643520 |
---|---|
author | Carr, Alice L.J. Inshaw, Jamie R.J. Flaxman, Christine S. Leete, Pia Wyatt, Rebecca C. Russell, Lydia A. Palmer, Matthew Prasolov, Dmytro Worthington, Thomas Hull, Bethany Wicker, Linda S. Dunger, David B. Oram, Richard A. Morgan, Noel G. Todd, John A. Richardson, Sarah J. Besser, Rachel E.J. |
author_facet | Carr, Alice L.J. Inshaw, Jamie R.J. Flaxman, Christine S. Leete, Pia Wyatt, Rebecca C. Russell, Lydia A. Palmer, Matthew Prasolov, Dmytro Worthington, Thomas Hull, Bethany Wicker, Linda S. Dunger, David B. Oram, Richard A. Morgan, Noel G. Todd, John A. Richardson, Sarah J. Besser, Rachel E.J. |
author_sort | Carr, Alice L.J. |
collection | PubMed |
description | C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes (UK GRID) cohort (N = 4,079), with β-cell loss in pancreas donors from the network for Pancreatic Organ donors with Diabetes (nPOD) biobank and the Exeter Archival Diabetes Biobank (EADB) (combined N = 235), stratified by recently reported age at diagnosis endotypes (<7, 7–12, ≥13 years) across increasing diabetes durations. The proportion of individuals with detectable C-peptide declined beyond the first year after diagnosis, but this was most marked in the youngest age group (<1-year duration: age <7 years: 18 of 20 [90%], 7–12 years: 107 of 110 [97%], ≥13 years: 58 of 61 [95%] vs. 1–5 years postdiagnosis: <7 years: 172 of 522 [33%], 7–12 years: 604 of 995 [61%], ≥13 years: 225 of 289 [78%]). A similar profile was observed in β-cell loss, with those diagnosed at younger ages experiencing more rapid loss of islets containing insulin-positive (insulin+) β-cells <1 year postdiagnosis: age <7 years: 23 of 26 (88%), 7–12 years: 32 of 33 (97%), ≥13 years: 22 of 25 (88%) vs. 1–5 years postdiagnosis: <7 years: 1 of 12 (8.3%), 7–12 years: 7 of 13 (54%), ≥13 years: 7 of 8 (88%). These data should be considered in the planning and interpretation of intervention trials designed to promote β-cell retention and function. |
format | Online Article Text |
id | pubmed-9233242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-92332422022-07-08 Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration Carr, Alice L.J. Inshaw, Jamie R.J. Flaxman, Christine S. Leete, Pia Wyatt, Rebecca C. Russell, Lydia A. Palmer, Matthew Prasolov, Dmytro Worthington, Thomas Hull, Bethany Wicker, Linda S. Dunger, David B. Oram, Richard A. Morgan, Noel G. Todd, John A. Richardson, Sarah J. Besser, Rachel E.J. Diabetes Pathophysiology C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes (UK GRID) cohort (N = 4,079), with β-cell loss in pancreas donors from the network for Pancreatic Organ donors with Diabetes (nPOD) biobank and the Exeter Archival Diabetes Biobank (EADB) (combined N = 235), stratified by recently reported age at diagnosis endotypes (<7, 7–12, ≥13 years) across increasing diabetes durations. The proportion of individuals with detectable C-peptide declined beyond the first year after diagnosis, but this was most marked in the youngest age group (<1-year duration: age <7 years: 18 of 20 [90%], 7–12 years: 107 of 110 [97%], ≥13 years: 58 of 61 [95%] vs. 1–5 years postdiagnosis: <7 years: 172 of 522 [33%], 7–12 years: 604 of 995 [61%], ≥13 years: 225 of 289 [78%]). A similar profile was observed in β-cell loss, with those diagnosed at younger ages experiencing more rapid loss of islets containing insulin-positive (insulin+) β-cells <1 year postdiagnosis: age <7 years: 23 of 26 (88%), 7–12 years: 32 of 33 (97%), ≥13 years: 22 of 25 (88%) vs. 1–5 years postdiagnosis: <7 years: 1 of 12 (8.3%), 7–12 years: 7 of 13 (54%), ≥13 years: 7 of 8 (88%). These data should be considered in the planning and interpretation of intervention trials designed to promote β-cell retention and function. American Diabetes Association 2022-07 2022-05-02 /pmc/articles/PMC9233242/ /pubmed/35499624 http://dx.doi.org/10.2337/db22-0097 Text en © 2022 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://diabetesjournals.org/journals/pages/license. |
spellingShingle | Pathophysiology Carr, Alice L.J. Inshaw, Jamie R.J. Flaxman, Christine S. Leete, Pia Wyatt, Rebecca C. Russell, Lydia A. Palmer, Matthew Prasolov, Dmytro Worthington, Thomas Hull, Bethany Wicker, Linda S. Dunger, David B. Oram, Richard A. Morgan, Noel G. Todd, John A. Richardson, Sarah J. Besser, Rachel E.J. Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration |
title | Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration |
title_full | Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration |
title_fullStr | Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration |
title_full_unstemmed | Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration |
title_short | Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration |
title_sort | circulating c-peptide levels in living children and young people and pancreatic β-cell loss in pancreas donors across type 1 diabetes disease duration |
topic | Pathophysiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233242/ https://www.ncbi.nlm.nih.gov/pubmed/35499624 http://dx.doi.org/10.2337/db22-0097 |
work_keys_str_mv | AT carralicelj circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT inshawjamierj circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT flaxmanchristines circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT leetepia circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT wyattrebeccac circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT russelllydiaa circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT palmermatthew circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT prasolovdmytro circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT worthingtonthomas circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT hullbethany circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT wickerlindas circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT dungerdavidb circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT oramricharda circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT morgannoelg circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT toddjohna circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT richardsonsarahj circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration AT besserrachelej circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration |